Alvocidib
Acute Monocytic Leukemia
National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Acute Monocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide Stanford University | Phase 3 | BBB |
Cytarabine Chinese PLA General Hospital | Phase 3 | BBB |
Daunomycin National Cancer Institute (NCI) | Phase 3 | BBB |
Cyclophosphamide ECOG-ACRIN Cancer Research Group | Phase 3 | BBB |
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- National Cancer Institute (NCI) | Phase 2 | BBB |
View all 49 →
Same molecule, other indications
Alvocidib is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative · Phase 2
71 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →